Thera-SAbDab

BRENTUXIMAB

>   Structural Summary
TherapeuticBrentuximab
TargetTNFRSF8
Heavy ChainQIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSA
Light ChainDIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb ADC
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedBristol-Myers Squibb, Celgene Corporation, Dana-Farber Cancer Institute, Fondazione Italiana Linfomi, Fox Chase Cancer Center, Immune Tolerance Network, Lymphoma Academic Research Organisation, Massachusetts General Hospital, National Cancer Institute (USA), National Institute of Allergy and Infectious Diseases, Seattle Genetics, Stanford University, Takeda, Takeda Oncology, UNC Lineberger Comprehensive Cancer Center, Washington University School of Medicine
Conditions ApprovedAnaplastic large cell lymphoma, Cutaneous T-cell lymphoma, Hodgkin's disease, Mycosis fungoides, T-cell lymphoma
Conditions ActiveAdult T-cell leukaemia-lymphoma, Diffuse large B cell lymphoma, Germ cell and embryonal neoplasms, Mastocytosis, Mesothelioma, Non-Hodgkin's lymphoma, Peripheral T-cell lymphoma, Sezary syndrome, Diffuse scleroderma
Conditions DiscontinuedGraft-versus-host disease, Leukaemia, Multiple myeloma, Solid tumours, Systemic lupus erythematosus
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]